• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtronic wins FDA nod to deliver PAH therapy with implantable pump

July 31, 2018 By Sarah Faulkner

Medtronic's SynchroMedMedtronic (NYSE:MDT) said today that it won FDA approval for its implantable drug-delivery system designed to administer United Therapeutics‘ (NSDQ:UTHR) pulmonary arterial hypertension drug, Remodulin.

United Therapeutics is slated to take the lead on commercial promotion of the drug-device system, with support from Medtronic.

The system includes Medtronic’s SynchroMed II implantable pump and a new intravascular catheter that delivers Remodulin intravenously to patients who have previously received Remodulin via an external infusion pump.

“External infusion pumps have been used to deliver prostacyclins for PAH, but managing the therapy places a significant burden on patients, interferes with their daily activities, and runs a high risk of infections,” Dr. David Steinhaus, GM of Medtronic’s heart failure business, said in prepared remarks. “This fully implantable drug delivery system was designed to address these serious patient care concerns.”

The product’s launch was delayed in April last year due to “complexities related to the parallel [regulatory] filings” that the companies pursued for the drug and the device.

Medtronic’s implantable drug pump faced its own problems last year after the FDA issued a Class I recall in March for the SynchroMed II and EL pumps due to a priming bolus issue. The two issues – the recall and the delayed launch – were not related, according to a Medtronic spokesperson.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Pharmaceuticals, Wall Street Beat Tagged With: Medtronic, United Therapeutics

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Reader Interactions

Comments

  1. Robert Reny says

    June 17, 2019 at 5:08 am

    Novitium Pharma’s generic sildenafil is now approved by the FDA for treating pulmonary arterial hypertension (PAH) treatment. Oral suspension of this dose will be10 mg/mL.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS